These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29369008)

  • 1. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
    J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-based virtual screening, molecular docking, QSAR and pharmacophore analysis of quercetin-associated potential novel analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2017 Dec; 37(6):600-610. PubMed ID: 28958213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
    Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
    Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
    Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
    Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homology models of the mutated EGFR and their response towards quinazoline analogues.
    Kotra S; Madala KK; Jamil K
    J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors.
    Doss GP; Rajith B; Chakraborty C; NagaSundaram N; Ali SK; Zhu H
    Sci Rep; 2014 Aug; 4():5868. PubMed ID: 25091415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico target specific design of potential quinazoline-based anti-NSCLC agents.
    Mohammadnejadi E; Razzaghi-Asl N
    J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
    Agarwal SM; Pal D; Gupta M; Saini R
    Curr Cancer Drug Targets; 2017; 17(7):617-636. PubMed ID: 28359250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
    Yu H; Li Y; Ge Y; Song Z; Wang C; Huang S; Jin Y; Han X; Zhen Y; Liu K; Zhou Y; Ma X
    Eur J Med Chem; 2016 Mar; 110():195-203. PubMed ID: 26829280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.
    Yoshikawa S; Kukimoto-Niino M; Parker L; Handa N; Terada T; Fujimoto T; Terazawa Y; Wakiyama M; Sato M; Sano S; Kobayashi T; Tanaka T; Chen L; Liu ZJ; Wang BC; Shirouzu M; Kawa S; Semba K; Yamamoto T; Yokoyama S
    Oncogene; 2013 Jan; 32(1):27-38. PubMed ID: 22349823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
    Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
    Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
    Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
    Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
    Konidala KK; Bommu UD; Pabbaraju N
    J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
    Patel HM; Pawara R; Ansari A; Noolvi M; Surana S
    Bioorg Med Chem; 2017 May; 25(10):2713-2723. PubMed ID: 28366268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.
    Asadollahi-Baboli M
    Mol Divers; 2016 Aug; 20(3):729-39. PubMed ID: 27209475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer.
    Ning J; Wu Q; Liu Z; Wang J; Lin X
    J Recept Signal Transduct Res; 2016; 36(1):37-44. PubMed ID: 26096169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.